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Pharmaceutical invention and research are increasingly focusing on delivery systems which enhance 
desirable therapeutic objectives while minimising side effects. Recent trends indicate that 
multiparticulate drug delivery systems are especially suitable for achieving controlled or delayed release 
oral formulations with low risk of dose dumping, flexibility of blending to attain different release patterns 
as well as reproducible and short gastric residence time. The release of drug from microparticles 
depends on a variety of factors including the carrier used to form the multiparticles and the amount of 
drug contained in them. Consequently, multiparticulate drug delivery systems provide tremendous 
opportunities for designing new controlled and delayed release oral formulations, thus extending the 
frontier of future pharmaceutical development. 
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INTRODUCTION 
Multi-particulate drug delivery systems are 
mainly oral dosage forms consisting of a 
multiplicity of small discrete units, each 
exhibiting some desired characteristics. In 
these systems, the dosage of the drug 
substances is divided on a plurality of subunit, 
typically consisting of thousands of spherical 






multiparticulate dosage forms are 
pharmaceutical formulations in which the 
active substance is present as a number of 
small independent subunits. To deliver the 
recommended total dose, these subunits are 
filled into a sachet and encapsulated or 
compressed into a tablet
4
. Multiparticulates 
are discrete particles that make up a multiple-
unit system. They provide many advantages 
over single-unit systems because of their 
small size. Multiparticulates are less 
dependent on gastric empty ting, resulting in 
less inter and intra-subject variability in 
gastrointestinal transit time. They are also 





Recently much emphasis is being 
laid on the development of multiparticulate 
dosage forms in preference to single unit 
systems because of their potential benefits 
such as increased bioavailability, reduced risk 
of systemic toxicity, reduced risk of local 
irritation and predictable gastric emptying
3
.  
There are many reasons for formulating a 
drug as a multiparticulate system for example, 
to facilitate disintegration in the stomach, or to 
provide a convenient, fast disintegrating tablet 
that dissolves in water before swallowing 
which can aid compliance in older patients 
and children. Multiparticulate systems show 
better reproducible pharmacokinetic behavior 
than conventional (monolithic) formulations. 
After disintegration which occurs within a few 
minutes often even within seconds, the 
individual subunit particles pass rapidly 
through the GI tract. If these subunits have 
diameters of less than 2mm, they are able to 
leave the stomach continuously, even if the 
pylorus is closed. These results in lower intra 
and inter individual variability in plasma levels 
and bioavailability. 
Drug safety may also be increased by using 
multiparticulate dosage forms, particularly for 
modified release systems. For example, if the 
film coat of a single-unit (monolithic) enteric 
coated tablet is damaged, the complete dose 
will be released into the stomach where it may 
cause pain or ulceration or reduced efficacy, 
depending on the reason for choosing the 
protection of the enteric coating. Equally, if 
there is damage to the film coating of a 
monolithic tablet with a sustained release 
formulation, this can lead to “dose dumping” 
and result in dramatic side effects. By 
contrast, in multiparticulate formulation, the 
release characteristics are incorporated into 
every single subunit and any damage only 
affects the release behavior of the subunit 
involved, which represents a small part of the 





SOME APPROACHES TO 
MULTIPARTICULATE FORMULATION 
 
A multiparticulate floating–pulsatile drug 
delivery system was developed using porous 
calcium silicate [RE(R)] and sodium alginate, 





An oral controlled onset extended release 
dosage form intended to approximate the 
chronobiology of rheumatoid arthritis was 
proposed for site specific release to the colon. 
The multiparticulate system consisting of drug 
loaded cellulose acetate cores encapsulated 
within Eudragit S-100 microcapsules was 
designed for chronotherapeutic delivery of 
ketoprofen
6
. The site-specific delivery of drugs 
to the colon has implications in a number of 
therapeutic areas, which include topical 
treatment of colonic disorders such as Crohn’s 
disease, ulcerative colitis, constipation, 





Multiparticulates approaches tried for colonic 
delivery includes formulations in the form of 
pellets, granules, microparticles and 
nanoparticles. Because of their smaller 
particle size compared to single unit dosage 
forms these systems are capable of passing 
through the GI tract easily, leading to low inter 
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and -intra subject variability. Moreover, 
multiparticulate systems are to be more 
uniformly dispersed in the GI tract and also 
ensure more uniform drug absorption
3
. A 
multiparticulate system of chitosan hydrogel 
beads has been investigated for colon-specific 
delivery of macromolecules using fluorescein 
is othiocyanate-labeled bovine serum albumin 




Multiparticulates may be prepared by several 
methods. Different methods require different 
processing conditions and produce 
multiparticulates of distinct qualities. Some of 
these methods may be broadly classified as 
pelletization, granulation, spray drying, and 
spray congealing. Drug particles may be 
entrapped within the multiparticulates or 
layered around them. Subsequently, these 
multiparticulates may be modified in many 
ways to achieve the desired drug release 
profile. 
One approach to the modification of drug 
release profile in multiparticulates is to coat 
them. Reasons for the application of coating 
onto maltiparticulates are to obtain functional 
coats, provide chemical stability, improve 
physical characteristics and enhance patient 
acceptance. Coats are formed from various 
polymeric coating materials broadly classified 
as aqueous polymer dispersions, polymer 
solutions, molten polymers and dry powders. 
Depending on the type of coating material 
used, functions such as sustained release 
(SR), targeted release, delayed release, and 
pulsatile release can be achieved.  
The most common method used for the 
application of coating onto multiparticulates is 
air suspension coating. Other methods include 
compression coating, solvent evaporation, 
coacervation, and interfacial complexation. It 
is also possible to form coated 
multiparticulates by spray drying and spray 
congealing 
2
. A multiparticulate composition 
may allow controlled release of the drug over 
a wide range of release rates, and permit the 
release rate to be set at a predetermined rate, 
such a formulation may be formed using a 
melt-congeal process which maintains the 
crystallinity of the drug during the melt-
congeal process 
9
. A multiparticulate delayed 
release system based on coated pellets 
containing an osmotic active ingredient has 
been prepared. The coating consisted of a 
semi permeable membrane of cellulose 
acetate. Following ingestion water penetrates 
into the core and forms a saturated solution of 
the soluble components. The osmotic 
pressure gradient induces a water influx 
resulting in a rapid expansion of the 
membrane leading to the formation of pores. 
The osmotic ingredient and the drug are 
released through these pores according to 
zero order kinetics. In comparison with the 
sodium chloride free formulation the inclusion 
of the osmotically active ingredient results in a 
completely different dissolution behavior. Lag 
time and dissolution rate were dependent on 





MECHANISM OF DRUG RELEASE FROM 
MULTI-PARTICULATES 
The mechanism of drug release from 
multiparticulates can be occur in the following 
ways: 
Diffusion  
On contact with aqueous fluids in the 
gastrointestinal tract (GIT), water diffuses into 
the interior of the particle. Drug dissolution 
occurs and the drug solutions diffuse across 
the release coat to the exterior. 
Erosion 
 Some coatings can be designed to erode 
gradually with time, thereby releasing the drug 
contained within the particle. 
Osmosis 
In allowing water to enter under the right 
circumstances, an osmotic pressure can be 
built up within the interior of the particle. The 
drug is forced out of the particle into the 




DESIGN OF MULTIPARTICULATE DRUG 
DELIVERY SYSTEMS 
The purpose of designing multiparticulate 
dosage form is to develop a reliable 
formulation that has all the advantages of a 
Dey  et al 
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single unit formulations and yet devoid of the 
danger of alteration in drug release profile and 
formulation behavior due to unit to unit 
variation, change in gastro –luminal pH and 
enzyme population. A generally accepted view 
is that multiparticulate systems perform better 
in vivo than single unit system, as they spread 
out through the length of the intestine cause 
less irritation, enjoy a slower transit through 
the colon and give a more reproducible drug 
release. As in the case of single unit dosage 
forms, for the purpose of the designing 
multiparticulate colon specific drug delivery 
system, the presence of specific bacterial 
    
 
Fig 1: Intestinal Protective Drug Absorption System Fig 2: Spheroidal Oral Drug Absorption System 
 
 
     
 
Fig 3: Programmable Oral Drug Absorption System   Fig  4: Diffucaps 
 
 
    Fig 5: Minitab 
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populations in the colon and increasing pH 
gradient have been extensively explored as 
triggering mechanism in order to initiate colon 
specific drug release. 
Multiparticulate crystalline drug 
compositions  
A multiparticulate for controlled release of a 
drug comprises  a crystalline drug, a glyceride 
having at least one alkylate substituent of not 
less than 16 carbon atoms, and a poloxamer, 
wherein at least 70 wt % of the drug in the 
multiparticulate is crystalline. The 
multiparticulate comprises crystalline drug 
particles embedded in the glyceride/ 
poloxamer mixture.   The poloxamer 16 is 
substantially homogeneously distributed 
throughout the glyceride 14 and is present as 
a separate phase from the glyceride 14
11
. 
Multiparticulates as NDDS 
Incorporating an existing medicine into a novel 
drug delivery system (NDDS) can significantly 
improve its performance in terms of efficacy, 
safety and improved patient compliance.  In 
the form of a NDDS, an existing drug 
molecule can get new life, thereby increasing 
its market value and competitiveness and 
even extending patent life
1
. 
Intestinal Protective Drug Absorption 
System 
Intestinal protective drug absorption system 
(IPDAS) (Figure 1) is a multiparticulate tablet 
technology that has been developed to 
enhance the gastric tolerability of potentially 
irritant or ulcerogenic drugs such as the 
NSAIDs. It consists of high density controlled 
release beads that are compressed into a 
tablet form. The beads may be manufactured 
by techniques such as extrusion 
spheronization and controlled release can be 
achieved with the use of different polymer 
systems to coat the resultant beads. 
Alternatively, the drug can also be coated into 
on an inert carrier such as non-pareil seeds to 
produce instant release multiparticulates. 
Controlled release can be achieved by the 
formation of a polymeric membrane onto 
these instant release multparticulates. Once 
an IPDAS tablet is ingested, it rapidly 
disintegrates and disperses beads containing 
the drug in the stomach which subsequently 
pass into the duodenum and along the 
gastrointestinal tract in a controlled and 
gradual manner, independent of the feeding 
state. Release of active ingredient from the 
multiparticulates occurs through a process of 
diffusion either through the polymeric 
membrane and /or the micro matrix of the 
polymer/active ingredient formed in the 
extruded/spheronized multiparticulates.   The 
intestinal protection of IPDAS is by virtue of 
the multiparticulate nature of the formulation 
which ensures wide dispersion of irritant drug 
throughout the gastrointestinal tract. 
Naprelan®, which is marketed in the United 
States, employs IPDAS technology. This 
innovative formulation of naproxen sodium is 
a unique controlled release formulation 
indicated both for acute and chronic pain
1,12
. 
Spheroidal oral drug absorption systems 
Spheroidal Oral Drug Absorption System 
(SODAS) (Figure 2) is a multiparticulate 
technology that enables the production of 
customized dosage forms and responds 
directly to individual drug candidate needs. It 
can provide a number of tailored drugs 
release profiles including immediate release of 
drug followed by sustained release to give rise 
to a fast onset of action which is mainted for 
24 hours. Alternatively, the opposite scenario 
can be achieved where drug release is 
delayed   for a number of hours
1,13
.              
Programmable Oral Drug Absorption 
System 
Programmable Oral Drug Absorption System 
(PRODAS) (Figure 3) is presented as a 
number of mini tablets contained in hard 
gelatin capsule. It thus combines the benefits 
of tableting technology within a capsule. It is 
possible to incorporate many different 
minitablets, each one formulated individually 
and programmed to release drug at different 
sites within the GIT. These combinations may 
include immediate release, delayed release, 
and/or controlled release mini tablets. It is also 
possible to incorporate mini tablets of different 
sizes so that high drug loading is possible. 
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Diffucaps 
In this multiparticulate system, drug profiles 
are created by layering an active drug onto a 
neutral core such as sugar spheres, crystals 
or granules followed by the application of  a  
rate-controlling, functional membrane (Figure 
4). The coating materials can be water 
soluble, pH dependent or independent or 
water insoluble depending on the individual 
needs of compound. The resultant beads are 
small in size approximately 1mm or less in 
diameter. By incorporating beads of differing 
drug release profiles into hard gelatin 
capsules, combination release profiles can be 
achieved. It is possible to customize any 
combination of sustained release, pulsatile 
release and immediate release profiles 
depending on the specific needs of the 
product.   
The drug layering process can be conducted 
either from aqueous or solvent based drug 
solutions. Eurand has also developed a 
formulation technology that combines the 
customized drug release offered by Diffucaps 
with technologies that enhance the solubility 
of insoluble drugs in the gastrointestinal tract. 
Eurand is using this technology to provide a 
degree of delivery control that goes beyond 
that of single technology systems. 
Diffucaps beads are small in size, 
approximately 1mm in diameter, and are filled 
into a capsule to create the final dosage 
form. Beads of differing drug release profiles 
can be easily combined in a single capsule 
providing high levels of control over release 
profiles. Diffucaps beads of different drugs 
can be combined to make convenient single 





The Eurand MINITABS technology (Figure 5) 
is unique in that it offers the advantages of a 
tablet combined with those of a 
multiparticulate drug form. Eurand MINITABS 
are tiny (2mm x 2mm) tablets containing gel-
forming excipients that control drug release 
rate. Additional membranes may be added to 
further control release rate. The small size of 
Eurand minitabs means that they can be filled 
into capsules as a final dosage form.                                                              
As a result, combination products can be 
developed to allow for two or more release 
profiles within a single capsule. Eurand 
minitabs offer high drug loading, the ability to 
fine tune release rates for targeted delivery 
and content uniformity for more accurate 
dosing. Eurand Minitabs offer high drug 
loading, a wide range of release rate designs, 
and fine tuning of these release rates. The 
capsules can be opened and the contents 
used as a "sprinkle" formulation 
1, 16. 
Stabilized Pellet Delivery System  
Stabilized pellet delivery system technology 
uses functional polymers or a combination of 
functional polymers and specific additives, 
such as composite polymeric materials to 
deliver a drug to a site of optimal absorption 
along the intestinal tract. The active drug is 
incorporated in multiparticulate dosage forms 
such as DIFFUCAPS or Eurand MINITABS, 
which are then subsequently coated with pH 
dependent/independent polymeric 
membranes that will deliver the drug to the 
desired site. These are then filled into hard 
gelatin capsules. This technology is designed 
specifically for unstable drugs and 
incorporates a pellet core of drug and 
protective polymer outer layer(s) 
1
. 
Pelletized Delivery System  
Pelletized Delivery System (PDS) is a 
sustained release system using pellets or 
beads manufactured using marumerization/ 
pheronization/pelletization techniques or by 
layering powders or solutions on nonpareil 
seeds. Release modulating polymers are 
sprayed on the beads using various coating 
techniques. The coated beads are filled in to 
hard gelatin capsules. Drug release occurs by 
diffusion associated with bioerosion or by 
osmosis via the surface membrane. The 
release mechanism can be pH-activated or 
pH-independent. The beads can be 





Pelletised tablet  
Pelletised tablet (Peltab
®
) system utilizes 
polymer-coated drug pellets or drug crystals, 
which are compressed into tablets. In order to 
provide a controlled release, a water insoluble 
Dey  et al 
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polymer is used to coat discrete drug pellets 
or crystals, which then can resist the action of 
fluids in the GIT. This technology incorporates 
a strong polymer coating enabling the coated 






Multiparticle Drug Dispersing Shuttle  
Multiparticle drug dispersing shuttle 
(Multipart
®
) consists of a tablet carrier for the 
delivery of controlled release beads or pellets 
through the GIT which preserves the integrity 
and release properties of the beads. The 
distribution of the beads is triggered by the 
disintegration of the tablet carrier in the 
stomach. Drug release from the beads is 
triggered by super disintegration of the tablets. 
It can be pH-activated or pH-independent and 
can occur by disintegration or osmosis. The 
beads can be formulated to produce first or 









 consists of immediate release 
beads made by extrusion/ spheronization/ 
pelletization techniques or by layering 
powders or solutions on nonpareil seeds. 
Release modulating polymers are sprayed on 
the beads using various coating techniques. 
The coated beads are filled in hard gelatin 
capsules. Drug release occurs by diffusion 
associated with bioerosion or by osmosis via 
the surface membrane. The release 
mechanism can be pH-activated or pH-
independent. The beads can be formulated to 










 technology is a multiparticulate 
system that enables high drug loading and is 
suitable for products that require granulation. 
This technology produces beads that are of 
controlled size and density using granulation, 
extrusion and spheronization techniques. This 
process is unique in that it allows for higher 
drug loading than other systems, is flexible 
and is suitable for use with sensitive materials 







KV/24 is a patented, multiparticulate drug 
delivery technology that encapsulates one or 
more drug compounds to achieve release in a 
pre-determined fashion over a 24-hour period 
after oral administration. KV/24 technology is 
based upon coating a neutral core (non-
pareiled bead) with a drug substance, then 
sequentially coating with one or more 
polymers to achieve a once-a day release 
profile. The drug can either be combined with 






Flashtab technology is a fast 
dissolving/disintegrating oral tablet 
formulation. It is a combination of taste 
masked multiparticulate active drug 
substances with specific excipients 
compressed into tablets. A disintegrating 
agent and a swelling agent are used in 
combination with coated drug particles in this 
formulation to produce a tablet that 
disintegrates in the mouth in less than one 
minute. These oro-dispersible tablets disperse 




InnoHerb      
This technology is used coating the pellets 
inside of the capsule, InnoHerb 
Phytogranules. The multiparticulate is made 
up of many micropellets or small beads 
containing active herbal compounds. The 
special coating for each plant extract contains 
top quality standardised dried extracts which 
assures efficacy and safety of the semi-
permeable membrane, improves stability, 
mask taste/smell and affords gastro-protection 
as well as promote controlled release of 






Layering process for multiparticulate 
dosage form  
Layering processes involve loading solid inert 
cores with drugs and/or excipients. Inert 
cores, placed in a suitable vessel such as a 
coating pan or a fluid bed, may be layered 
according to different methods. Some 
methods consist of spraying onto the cores a 
Dey  et al 
Trop J Pharm Res September 2008; 7 (3) 1074 
solution/suspension containing both drug and 
binding agent. Others are based on layering 
the drug directly in powdery form where drug 
loading occurs by gravity and adhesion is 
ensured by a liquid binder sprayed onto the 
cores.  
The layering process is particularly suitable for 
production of small drug loaded units, 
multiples of which are placed into capsules for 
patient delivery. In the case of spherical inert 
cores such as non-pareils, the layering 
techniques from solution/suspensions produce 
homogeneous drug loaded particles, which 
retain an approximately spherical shape. They 
are therefore particularly suitable for 
successively film coating to build up the 
particle with the aim of providing a desired 




Delayed release oral polypeptides  
In one embodiment, the composition further 
includes an inert core. The inert core can be, 
e.g., a pellet, sphere or bead made up of 
sugar, starch, microcrystalline cellulose or any 
other pharmaceutically acceptable inert 
excipient. A preferred inert core is a 
carbohydrate, such as a monosaccharide, 
disaccharide, or polysaccharide, i.e., a 
polymer including three or more sugar 
molecules. An example of a suitable 
carbohydrate is sucrose. In some embodi-
ents, the sucrose is present in the composition 
at a concentration of 60-75%. 
When the bioactive polypeptide is IL-11, the 
IL-11 layer is preferentially provided with a 
stabilizer such as methionine, glycine, 
polysorbate 80 and phosphate buffer, and/or a 
pharmaceutically acceptable binder, such as 
hydroxypropyl methylcellulose, povidone or 
hydroxypropyl ‘cellulose. The composition can 
additionally include one or more 
pharmaceutical excipients. Such pharmaceu-
ical excipients include, e.g., binders, 
disintegrants, fillers, plasticizers, lubricants, 
glidants, coatings and suspending/ ispersing 
agents. In some embodiments, the 
composition is provided as a multiparticulate 
system that includes a plurality of enteric 
coated, IL-11 layered pellets in a capsule 
dosage form. The enteric coated IL-11 pellets 
include an inert core, such as a carbohydrate 
sphere, a layer of IL-11 and an enteric coat. 
The enteric coat can include, e.g., a pH 
dependent polymer, a plasticizer, and an 
antisticking agent/glidant. Preferred polymers 
include e.g., methacrylic acid copolymer, 
cellulose acetate phthalate, hydroxyl propyl 
methylcellulose phthalate, polyvinyl acetate 
phthalate, shellac, hydroxylpropyl 
methylcellulose acetate succinate and 
carboxymethylcellulose.   Preferably, an inert 
seal coat is present in the composition as a 
barrier between the IL-11 layer and enteric 
coat. The inert seal coat can be e.g. hydroxyl 
propyl methyl cellulose, povidone, 
hydroxylpropyl cellulose or another 
pharmaceutically acceptable binder. 
Suitable sustained release polymers include, 
e.g., amino methacrylate copolymers 
(Eudragit RL, Eudragit RS), ethylcellulose or 
hydroxypropyl methylcellulose. In some 
embodiments, the methacrylic acid copolymer 
is a pH dependent anionic polymer solubilizing 
above pH 5.5. The methacrylic acid copolymer 
can be provided as a dispersion and be 
present in the composition at a concentration 








In a preferred embodiment, illustrated by way 
of example, there is provided a supply of gas-
developing components as well as a number 
of film-like, stacked individual particles which 
consist of a mucoadhesive, active substance-
containing layer and of a backing layer 
controlling the direction of active substance 
release, these components being located 
within a polymer enclosure which is resistant 
to gastric juice but permeable to intestinal 
juice. Here, the active substance may be 
present embedded in the film-like component. 
The process for the production of a gastric 
juice-resistant device,  consisting of at least 
one active substance in the form of a 
multiparticulate preparation with muco-
adhesive properties, and of a blowing agent 
which on contact with liquid produces gas 
individual particles being enclosed by a gastric 
juice-resistant, intestinal juice-soluble polymer 
Dey  et al 
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enclosure, is as follows: (a)  transfer of a 
polymer material in web form to a moulding 
board provided with bores, and applying a 
vacuum to form the compartments of the 
polymer enclosure;  (b)alternately filling-in the 
active substance-containing preparation and 
the blowing agent-containing preparation; (c) 
superposing a second polymer web, and 
closing the compartments by sealing with 
application of heat and pressure; and (d) 






The market for drug delivery system has come 
a long way and will continue to grow at an 
impressive rate. Today’s drug delivery 
technologies enable the incorporation of drug 
molecules into a new delivery system, thus 
providing numerous therapeutic and 
commercial advantages. Multiparticulate drug 
delivery systems provide several all the 
advantages including greater flexibility and 
adaptability of microparticulate dosage forms 
which gives clinicians and those engaged in 
product development powerful new tools to 
optimize therapy. It is little wonder therefore, 
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